All In Biotech

Free tool

FAERS Monitor: Bethkis

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 201820 or its brand name (Bethkis, Tobramycin). Reports on generic versions are filed under their own applications.

Reports

14,537

Serious

11,256

77% of reports

Hospitalization

7,080

Death reported

1,372

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use1,324
  • pneumonia938
  • infective pulmonary exacerbation of cystic fibrosis784
  • dyspnoea759
  • drug ineffective700
  • acute kidney injury688
  • death575
  • hospitalisation550
  • cough534
  • cystic fibrosis515
  • condition aggravated508
  • infection491
  • pyrexia443
  • fatigue424
  • diarrhoea400

Reports by year received

View as table
YearReports
200480
200597
200677
2007124
200891
200999
2010101
2011208
2012189
2013165
2014273
2015536
2016696
2017762
20181,328
20192,040
20201,899
20211,145
20221,032
2023871
20241,090
2025947
2026687

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,039,622 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
infective pulmonary exacerbation of cystic fibrosisSignal784243.3226.0161,784
cystic fibrosisSignal515148.3135.668,218
acute kidney injurySignal6886.56.13,225
hospitalisationSignal5505.24.81,865
infectionSignal4914.94.51,536
pneumoniaSignal9384.23.92,314
coughSignal5342.82.5604
condition aggravatedSignal5082.42.2427
off label useSignal1,3242.22.1890
dyspnoea7591.91.8354
pyrexia4431.91.7176
death5751.00.91
diarrhoea4000.90.85
fatigue4240.80.725
drug ineffective7000.80.752

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.